CQAs are identified during which stage of product development? Response:

Question

Options

• AOnly at commercial scale
• BDuring clinical trials
• CFrom initial development through commercialization
• DAfter the first batch is produced

• A
  6% (3)
• B
  2% (1)
• C
  82% (40)
• D
  10% (5)

Explanation

Option C is correct because Critical Quality Attributes (CQAs) are identified and refined iteratively across the entire product lifecycle - from early formulation and process development through late-stage clinical studies and into commercial manufacturing. ICH Q8 and Q9 guidelines explicitly describe CQA identification as a continuous, risk-based activity that evolves as scientific understanding deepens.

Why the distractors are wrong:

• A (Only at commercial scale) is wrong because waiting until commercial scale would mean critical quality decisions were made blindly during development, creating unacceptable regulatory and patient safety risk.
• B (During clinical trials) is too narrow - CQAs begin emerging during pre-clinical and early formulation work, well before clinical trials.
• D (After the first batch) confuses CQA identification with process characterization; you need CQAs before making batches so you know what to measure and control.

Memory tip: Think of CQAs as living in a "cradle-to-market" lifecycle - just like the product itself. The acronym CQA = Continuous Quality Assessment (unofficial, but useful) reminds you it spans the full development continuum, not a single point in time.

No community discussion yet for this question.